End Stage Renal DiseasePhase 1NCT00460863
Effects of Hemodialysis on the Sleep/Wake Cycle
A Phase 1 study testing using cool versus warm dialysate during hemodialysis in people with End Stage Renal Disease, run by Emory University at 1 site in United States.
Trial summary
The purpose of this study is to test a novel application of an existing treatment - using col dialysate (often used to treat hypotension) as opposed to warm dialysate (standard treatment) during hemodialysis for its ability to stabilize the sleep/wake cycle of patients receiving this chronic treatment Read more about this study
- Who is it for?
- Ages 21 to 75 years
- Conditions the study is for
- End Stage Renal Disease
- What is being tested?
- using cool versus warm dialysate during hemodialysis
- Type of treatment
- Surgery or procedure
- How many people
- 58 participants
- Where
- 1 siteUnited States
- Study dates
- Apr 2003to Dec 2007
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 21 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- All races
- Cause of renal failures - diabetes, hypertension, glomerulonephritis, or polycystic kidney disease
- Ability to read and write in English hemodialysis three times a week for at least 4 months
- Clinically stable
- KT/V > 1.0
Who cannot join
None listed.
Trial locations and contacts
1 site in 1 country.
United States1 site
Nell Hodgson Woodruff School of Nursing
Atlanta, Georgia, 30322
About this study
Official title: Effects of Hemodialysis on the Slee/Wake Cycle of Patients on Chronic Hemodialysis
The purpose of this study is to test a novel application of an existing treatment - using col dialysate (often used to treat hypotension) as opposed to warm dialysate (standard treatment) during hemodialysis for its ability to stabilize the sleep/wake cycle of patients receiving this chronic treatment
Read the detailed description
This competing continuation proposal follows NR04340, "The Effects of Hemodialysis on the Sleep/ Wake Cycle", and seeks to test the efficacy of altering dialysate temperature on nocturnal sleep and daytime sleepiness in patients on chronic hemodialysis (HD). During the initial funding period, we examined the effects of HD and the time of its administration on sleep and waking. The major findings were that, in comparison to a group of control subjects with renal failure not yet on dialysis, HD subjects had reduced nocturnal total sleep time and sleep efficiency and increased numbers of brief arousals. One-third of HD subjects had abnormal, objectively measured daytime sleepiness, significant predictors of which were indices of nocturnal sleep disorders and duration of HD treatment. These effects occurred independent of treatment time of day. The negative influence of daytime sleepiness on life quality and functioning that we also found highlights the importance of the development and testing of interventions designed to address these changes. Furthermore, the recently described relationship between sleep disorders/sleepiness and cardiovascular disease leading cause of death in HD patients underscores the importance of this work.
Within the context of the Two-Process Model of Sleep Regulation and the well-described relationship between sleep/wake state and body temperature (BT), the data from additional studies we have conducted indicate that HD associated heat production contributes to its iatrogenic effects on the sleep/wake cycle. Consistent with other reports, we have shown that HD causes an increase in BT and, furthermore, alters its course across the day. We have also shown that BT and state sleepiness predictably covary across the duration of HD and that HD is associated with increased levels of both subjective and objective measurements of sleepiness. From both theoretical and physiological perspectives, one would predict that these HD-induced changes would place patients at high-risk for sleep/wake disturbances. In fact, both the nocturnal and daytime polysomnographic studies we conducted during our initial funding period demonstrate the severity of the sleep/wake problems experienced by this group. Previously tested interventions designed to improve the sleep of HD patients, such as normalizing hematocrit and performing slow, nocturnal HD, have decreased periodic limb movements and sleep apnea respectively, but have failed to significantly improve other indices of nocturnal sleep quality. We thus conducted a pilot study to test our hypothesis that treatment induced changes in BT contribute to the fragmented nocturnal sleep seen in this group by using cool dialysate (an existing intervention used to reduce hypotension) to block heat production and stabilize the sleep/wake cycle. Preliminary results demonstrated that, after one treatment, this intervention markedly normalized the rhythm of BT and improved indices of nocturnal sleep quantity and quality. Therefore, a major component of this proposal is to test a novel application for a safe, non-pharmacologic, cost-effective intervention that is already in use in clinical practice - using cool dialysate during HD to help stabilize the sleep/wake cycle of chronic HD patients. We will also evaluate its effects on selected sleep-related physiologic, psychological, behavioral, and general health outcomes.
This study, a randomized, single-blinded, control group clinical trial, represents the logical progression of a program of research devoted to the development of interventions designed to optimize the sleep/wake patterns of patients on chronic HD. The specific aims and associated hypotheses are:
- To test the effects of using cool dialysate during HD in comparison to warm dialysate (standard treatment) on the sleep/wake cycle of patients with chronic renal failure. H1 HD subjects will have improved nocturnal sleep (objective and subjective measures of sleep latency, total sleep time, sleep efficiency, and sleep disturbance) when dialyzed with cool dialysate in comparison to a warm dialysate. H2 HD subjects will have decreased daytime sleepiness (physiologic, manifest, and introspective) when dialyzed with cool dialysate in comparison to warm dialysate .
- To test the effects of using cool dialysate during HD in comparison to warm dialysate on other sleep-related physiological, psychological, behavioral, and general health outcomes.
H3 HD subjects will demonstrate improvement in selected sleep-related physiological (distal/proximal skin gradient and axillary body temperature rhythm), psychological (mood), behavioral (daily rest/activity), and general health outcomes (quality of life and functional status) when dialyzed with cool dialysate in comparison to warm dialysate.
- Conditions
- End Stage Renal Disease
- Being tested
- using cool versus warm dialysate during hemodialysis
- Keywords
- sleep, hemodialysis, daytime sleepiness, temperature
- Medical subject headings
- Kidney Failure, Chronic, Disorders of Excessive Somnolence
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
using cool versus warm dialysate during hemodialysisProcedure or surgery
What is being measured
The primary outcome is the main question the study is designed to answer.
Polysomnographic measures of sleep
Measured: At three time points over the nine month study period
Polysomnographic measures of daytime sleepiness
Measured: At three time points over the nine month study period
Distal/proximal skin temperature gradient
Measured: At three time points during the nine month study period
Secondary outcomes (5)
Subjective measure of sleep quality
Measured: Monthly during the nine month study period
Subjective measure of daytime sleepiness
Measured: Monthly during the nine month study period
Subjective measure of mood
Measured: Monthly during the nine month study period
Subjective measure of quality of life
Measured: Monthly during the nine month study period
Subjective measure of functional health status
Measured: Monthly during the nine month study period
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Apr 2007 (estimated)
- Study startApr 2003
- Primary completionDec 2007
- Study completionDec 2007
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for End Stage Renal DiseaseStudies of the same condition, open and under way.
- More trials run by Emory UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 58 participants (actual)
Sponsor and investigators
- Lead sponsor
- Emory University
- Sponsor type
- University, hospital or other
- Collaborators
- National Institute of Nursing Research (NINR)
- Responsible party
- Principal investigator, Sandra B. Dunbar, RN, Emory University
- Investigators
- Kathy P Parker, PhD, Principal investigator, Emory University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00460863
- Sponsor's protocol ID
- 0602-2002
- Other IDs
- R01NR004340, 72728732
- Status last verified
- May 2008
- First submitted
- 16 Apr 2007
- Last updated
- 24 Apr 2014
- Results posted
- No
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 24 Apr 2014. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effects of Hemodialysis on the Slee/Wake Cycle of Patients on Chronic Hemodialysis
- ClinicalTrials.gov ID
- NCT00460863
- Acronym / sponsor ID
- 0602-2002
- Conditions
- End Stage Renal Disease
- Keywords
- sleep, hemodialysis, daytime sleepiness, temperature
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 58 participants (actual)
- Lead sponsor
- Emory UniversityUniversity, hospital or other
- Collaborators
- National Institute of Nursing Research (NINR)
- Study start
- Apr 2003
- Primary completion
- Dec 2007 (actual)
- Study completion
- Dec 2007 (actual)
- First posted
- 17 Apr 2007 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to test a novel application of an existing treatment - using col dialysate (often used to treat hypotension) as opposed to warm dialysate (standard treatment) during hemodialysis for its ability to stabilize the sleep/wake cycle of patients receiving this chronic treatment
Detailed description
This competing continuation proposal follows NR04340, "The Effects of Hemodialysis on the Sleep/ Wake Cycle", and seeks to test the efficacy of altering dialysate temperature on nocturnal sleep and daytime sleepiness in patients on chronic hemodialysis (HD). During the initial funding period, we examined the effects of HD and the time of its administration on sleep and waking. The major findings were that, in comparison to a group of control subjects with renal failure not yet on dialysis, HD subjects had reduced nocturnal total sleep time and sleep efficiency and increased numbers of brief arousals. One-third of HD subjects had abnormal, objectively measured daytime sleepiness, significant predictors of which were indices of nocturnal sleep disorders and duration of HD treatment. These effects occurred independent of treatment time of day. The negative influence of daytime sleepiness on life quality and functioning that we also found highlights the importance of the development and testing of interventions designed to address these changes. Furthermore, the recently described relationship between sleep disorders/sleepiness and cardiovascular disease leading cause of death in HD patients underscores the importance of this work.
Within the context of the Two-Process Model of Sleep Regulation and the well-described relationship between sleep/wake state and body temperature (BT), the data from additional studies we have conducted indicate that HD associated heat production contributes to its iatrogenic effects on the sleep/wake cycle. Consistent with other reports, we have shown that HD causes an increase in BT and, furthermore, alters its course across the day. We have also shown that BT and state sleepiness predictably covary across the duration of HD and that HD is associated with increased levels of both subjective and objective measurements of sleepiness. From both theoretical and physiological perspectives, one would predict that these HD-induced changes would place patients at high-risk for sleep/wake disturbances. In fact, both the nocturnal and daytime polysomnographic studies we conducted during our initial funding period demonstrate the severity of the sleep/wake problems experienced by this group. Previously tested interventions designed to improve the sleep of HD patients, such as normalizing hematocrit and performing slow, nocturnal HD, have decreased periodic limb movements and sleep apnea respectively, but have failed to significantly improve other indices of nocturnal sleep quality. We thus conducted a pilot study to test our hypothesis that treatment induced changes in BT contribute to the fragmented nocturnal sleep seen in this group by using cool dialysate (an existing intervention used to reduce hypotension) to block heat production and stabilize the sleep/wake cycle. Preliminary results demonstrated that, after one treatment, this intervention markedly normalized the rhythm of BT and improved indices of nocturnal sleep quantity and quality. Therefore, a major component of this proposal is to test a novel application for a safe, non-pharmacologic, cost-effective intervention that is already in use in clinical practice - using cool dialysate during HD to help stabilize the sleep/wake cycle of chronic HD patients. We will also evaluate its effects on selected sleep-related physiologic, psychological, behavioral, and general health outcomes.
This study, a randomized, single-blinded, control group clinical trial, represents the logical progression of a program of research devoted to the development of interventions designed to optimize the sleep/wake patterns of patients on chronic HD. The specific aims and associated hypotheses are:
- To test the effects of using cool dialysate during HD in comparison to warm dialysate (standard treatment) on the sleep/wake cycle of patients with chronic renal failure. H1 HD subjects will have improved nocturnal sleep (objective and subjective measures of sleep latency, total sleep time, sleep efficiency, and sleep disturbance) when dialyzed with cool dialysate in comparison to a warm dialysate. H2 HD subjects will have decreased daytime sleepiness (physiologic, manifest, and introspective) when dialyzed with cool dialysate in comparison to warm dialysate .
- To test the effects of using cool dialysate during HD in comparison to warm dialysate on other sleep-related physiological, psychological, behavioral, and general health outcomes.
H3 HD subjects will demonstrate improvement in selected sleep-related physiological (distal/proximal skin gradient and axillary body temperature rhythm), psychological (mood), behavioral (daily rest/activity), and general health outcomes (quality of life and functional status) when dialyzed with cool dialysate in comparison to warm dialysate.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
Who may qualify
- Ages
- 21 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- All races
- Cause of renal failures - diabetes, hypertension, glomerulonephritis, or polycystic kidney disease
- Ability to read and write in English hemodialysis three times a week for at least 4 months
- Clinically stable
- KT/V > 1.0
Key exclusion criteria (0 listed)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| using cool versus warm dialysate during hemodialysis | Procedure or surgery | – |
Primary outcome
Polysomnographic measures of sleep
Time frame: At three time points over the nine month study period
Polysomnographic measures of daytime sleepiness
Time frame: At three time points over the nine month study period
Distal/proximal skin temperature gradient
Time frame: At three time points during the nine month study period
5 secondary outcomes
Subjective measure of sleep quality
Time frame: Monthly during the nine month study period
Subjective measure of daytime sleepiness
Time frame: Monthly during the nine month study period
Subjective measure of mood
Time frame: Monthly during the nine month study period
Subjective measure of quality of life
Time frame: Monthly during the nine month study period
Subjective measure of functional health status
Time frame: Monthly during the nine month study period
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Apr 2014.
Related trials for End Stage Renal Disease
Active, not recruitingPhase 2
Safety and Efficacy of Empagliflozin in Hemodialysis
End Stage Renal Disease
Not yet recruiting
Hypothermic Kidney Machine Perfusion With Omnisol
End Stage Renal Disease (ESRD), Kidney Transplant
Recruiting
Guiding Optimal Blood Pressure Management in Peritoneal Dialysis Pilot Trial
End Stage Kidney Disease (ESKD), Hypertension (HTN)
RecruitingObservational study
Physical Impairments in Children With Chronic Renal Failure
Chronic Kidney Failure, Chronic Kidney Diseases
RecruitingPhase 1
A Study to Test the Safety of the Study Drug Fosmanogepix and How the Body Handles It in Adults With Severe Kidney Failure on Dialysis
End Stage Renal Disease on Dialysis, Adult
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Kathy P Parker, PhD principal investigator
Emory University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing using cool versus warm dialysate during hemodialysis in people with End Stage Renal Disease, run by Emory University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 24 Apr 2014. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Polysomnographic measures of sleep (time frame: At three time points over the nine month study period). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Apr 2014.